Seres Therapeutics Inc. (MCRB): Skating on Thin Ice? We Know the Answer – News Heater
Home  »  Business   »  Seres Therapeutics Inc. (MCRB): Skating on Thin Ic...

Seres Therapeutics Inc. (MCRB): Skating on Thin Ice? We Know the Answer

Seres Therapeutics Inc. (NASDAQ:MCRB) went up by 10.49% from its latest closing price compared to the recent 1-year high of $25.06. The company’s stock price has collected 14.08% of gains in the last five trading sessions.

Is It Worth Investing in Seres Therapeutics Inc. (NASDAQ :MCRB) Right Now?

Plus, the 36-month beta value for MCRB is at 3.25. Opinions of the stock are interesting as 7 analysts out of 8 who provided ratings for Seres Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 1 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $14.00, which is $10.22 above the current price. MCRB currently public float of 83.92M and currently shorts hold a 5.65% ratio of that float. Today, the average trading volume of MCRB was 992.81K shares.

MCRB’s Market Performance

MCRB stocks went up by 14.08% for the week, with a monthly drop of -7.33% and a quarterly performance of -56.59%, while its annual performance rate touched -85.93%. The volatility ratio for the week stands at 10.85% while the volatility levels for the past 30 days are set at 10.65% for Seres Therapeutics Inc. The simple moving average for the period of the last 20 days is -1.20% for MCRB stocks with a simple moving average of -53.50% for the last 200 days.

Analysts’ Opinion of MCRB

Many brokerage firms have already submitted their reports for MCRB stocks, with Goldman repeating the rating for MCRB by listing it as a “Sell.” The predicted price for MCRB in the upcoming period, according to Goldman is $7 based on the research report published on July 23rd of the previous year 2021.

Goldman, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $24. The rating they have provided for MCRB stocks is “Neutral” according to the report published on May 18th, 2021.

Chardan Capital Markets gave a rating of “Buy” to MCRB, setting the target price at $30 in the report published on March 05th of the previous year.

MCRB Trading at -25.21% from the 50-Day Moving Average

After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.39% of loss for the given period.

Volatility was left at 10.65%, however, over the last 30 days, the volatility rate increased by 10.85%, as shares sank -11.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.30% lower at present.

During the last 5 trading sessions, MCRB rose by +14.08%, which changed the moving average for the period of 200-days by -53.25% in comparison to the 20-day moving average, which settled at $3.18. In addition, Seres Therapeutics Inc. saw -62.06% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for MCRB

Current profitability levels for the company are sitting at:

  • -45.70 for the present operating margin

The net margin for Seres Therapeutics Inc. stands at -45.25. Equity return is now at value -70.90, with -25.90 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.69.

Is Kimberly-Clark Corporation (KMB) a Keeper?

Kimberly-Clark Corporation (NYSE:KMB) went up by 3.54% from its latest closing price compared to the recent 1-year high of $145.79. The company’s stock price has